Centene Corporation $CNC Shares Sold by Caisse Des Depots ET Consignations

Caisse Des Depots ET Consignations reduced its position in Centene Corporation (NYSE:CNC) by 33.9% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 45,257 shares of the company’s stock after selling 23,198 shares during the quarter. Caisse Des Depots ET Consignations’ holdings in Centene were worth $1,615,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of CNC. WPG Advisers LLC grew its position in Centene by 44.5% during the 3rd quarter. WPG Advisers LLC now owns 915 shares of the company’s stock worth $33,000 after purchasing an additional 282 shares during the last quarter. Versant Capital Management Inc boosted its stake in shares of Centene by 11.6% during the third quarter. Versant Capital Management Inc now owns 3,421 shares of the company’s stock worth $122,000 after buying an additional 355 shares during the period. Snowden Capital Advisors LLC increased its position in Centene by 8.0% in the 2nd quarter. Snowden Capital Advisors LLC now owns 5,073 shares of the company’s stock valued at $275,000 after acquiring an additional 374 shares during the period. Financial Network Wealth Advisors LLC raised its stake in Centene by 54.9% during the 3rd quarter. Financial Network Wealth Advisors LLC now owns 1,100 shares of the company’s stock valued at $39,000 after acquiring an additional 390 shares during the last quarter. Finally, Geneos Wealth Management Inc. lifted its position in Centene by 29.8% during the 2nd quarter. Geneos Wealth Management Inc. now owns 1,897 shares of the company’s stock worth $103,000 after acquiring an additional 435 shares during the period. Hedge funds and other institutional investors own 93.63% of the company’s stock.

Key Centene News

Here are the key news stories impacting Centene this week:

• Positive Sentiment: Zacks/MSN published pieces arguing Centene is a long‑term value stock, highlighting attractive valuation metrics and the company’s scale in government-sponsored health plans; this kind of favorable narrative can support investor demand. Read More. Read More.
• Positive Sentiment: Centene’s community outreach via Superior HealthPlan and The Centene Foundation (No One Eats Alone program in Texas schools) is positive for brand and ESG perception—helps long‑term reputation with payors and state partners. Read More.
• Positive Sentiment: Deutsche Bank raised its price target to $39 (from $32) and kept a Hold rating—an upward revision that signals modestly improved analyst expectations even if the rating stayed conservative. Read More.
• Positive Sentiment: TD Cowen also raised its target to $38 (from $34) and maintained a Hold—another incremental upgrade to analyst targets that can support the stock after recent volatility. Read More.
• Neutral Sentiment: Argus moved Centene to a Hold—an analyst change that reduces downside concern but is not a clear buy signal. Read More.
• Neutral Sentiment: Cantor Fitzgerald reaffirmed a Neutral rating, keeping consensus sentiment cautious given regulatory and margin pressures. Read More.
• Neutral Sentiment: Morgan Stanley maintained its Hold on Centene, consistent with the mixed analyst tone—supportive of stability but not a catalyst for a large rerating. Read More.
• Negative Sentiment: Axios/other outlets report Centene is among insurers to receive subpoenas from a House panel—this introduces regulatory and legal risk that could pressure sentiment and create short‑term volatility. Read More.

Analysts Set New Price Targets

Several research firms have recently commented on CNC. UBS Group set a $42.00 price target on Centene and gave the stock a “neutral” rating in a research note on Thursday, October 30th. Weiss Ratings restated a “sell (d)” rating on shares of Centene in a research report on Wednesday, January 21st. Truist Financial lifted their target price on shares of Centene from $45.00 to $47.00 and gave the company a “buy” rating in a report on Monday, January 5th. Robert W. Baird increased their price target on shares of Centene from $28.00 to $36.00 and gave the stock a “neutral” rating in a report on Thursday, December 11th. Finally, Argus raised Centene to a “hold” rating in a report on Monday. Three research analysts have rated the stock with a Buy rating, fourteen have given a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $41.50.

Centene Stock Up 2.1%

Centene stock opened at $40.43 on Thursday. Centene Corporation has a fifty-two week low of $25.08 and a fifty-two week high of $66.03. The firm has a market capitalization of $19.87 billion, a price-to-earnings ratio of -2.97, a price-to-earnings-growth ratio of 0.87 and a beta of 0.48. The stock’s fifty day moving average is $42.08 and its two-hundred day moving average is $36.18. The company has a debt-to-equity ratio of 0.87, a quick ratio of 1.08 and a current ratio of 1.10.

Centene (NYSE:CNC) last released its quarterly earnings data on Friday, February 6th. The company reported ($1.19) EPS for the quarter, topping the consensus estimate of ($1.22) by $0.03. The business had revenue of $49.73 billion for the quarter, compared to analyst estimates of $48.41 billion. Centene had a negative net margin of 3.43% and a positive return on equity of 4.25%. The business’s revenue for the quarter was up 21.9% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.80 EPS. Centene has set its FY 2026 guidance at 3.000-3.000 EPS. Analysts predict that Centene Corporation will post 6.86 EPS for the current fiscal year.

Centene Profile

Centene Corporation (NYSE: CNC) is a diversified, multi-national healthcare enterprise that specializes in providing services to government-sponsored and national health programs. The company primarily acts as a managed care organization, delivering healthcare coverage and administering benefits for Medicaid, the Children’s Health Insurance Program (CHIP), Medicare Advantage, and individual marketplace plans. Centene also contracts with federal and state agencies to manage specialty care programs and community-based services for vulnerable populations.

Centene’s offerings extend beyond traditional insurance to include a range of specialty and support services.